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Dear Sirs, 
We read with great interest the paper by Strassburger-Krogias and colleagues 
showing a significant effect of dimethyl fumarate (DMF) on disability progression in 
progressive multiple sclerosis (MS) patients.(1) They enrolled 26 patients, 12 
affected by primary progressive  MS and 14 with secondary progressive MS of whom 
18 were treated with Fumaderm (Biogen Idec GmbH, Ismaning, Germany) and 8 on 
pharmacy prepared DMF. During a total mean follow-up period of 13.2 ± 7.5 months, 
57.7% of patients did not experience any disability progression and 19.2% of them 
showed an improvement of their disability measured with Expanded Disability Status 
Score (EDSS), with a overall favorable safety profile. There was no significant 
difference between the Fumaderm and DMF. 
DMF is one of the new oral drugs available for the treatment of relapsing MS. The 
exact mechanism of action of DMF is still under research and seems to involve the 
modulation of the immune response, the interference with the intracellular redox 
balance and possibly also an important effect on mitochondria, by inhibition of the 
mitochondrial respiratory complex II succinate dehydrogenase whose reaction 
product is precisely fumarate, and by activating the human mitochondrial NAD(P)+-
dependent malic enzyme.(2,3)  
Following the encouraging results on RRMS patients (4,5), and considering the 
multifaceted effects of DMF, a phase 3 study was planned and to be commenced in 
secondary progressive MS (SPMS) patients (Biogen INSPIRE study NCT02430532).  
However, despite the recent negative results from the natalizumab phase 3 study in 
SPMS, [ASCEND, (NCT01416181)], the decision made by Biogen to close the 
INSPIRE study seems at least disappointing, especially as the mechanisms of action 
of natalizumab and DMF are very different.  
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Although we agree that neurodegeneration, rather than inflammation, should be the 
primary therapeutic target in progressive MS, DMF has important effects on the 
immune response that may be relevant in progressive MS. Longbrake and 
colleagues (6) recently analyzed and characterized circulating blood leukocytes in 41 
stable MS patients treated with DMF and found that circulating CD8+ and CD4+ T 
cells, CD56dim natural killer (NK) cells, CD19+ B cells and plasmacytoid dendritic 
cells were lower in the lymphopenic MS patients compared to either control, with no 
changes of CD56hi NK cells, monocytes or myeloid dendritic cells. Whether 
lymphopenic or not, within the CD4+ and CD8+ subsets, they found a reduction of 
memory cells and a relative expansion of naïve cells. 
Relevant to DMF, there are two potential mechanisms pertinent to progressive MS. 
Firstly, the percentage of circulating CD56dim NK lymphocytes expressing perforin, a 
pore forming cytolytic protein found in the granules of cytotoxic cells, has been 
demonstrated to be increased in both PPMS and SPMS.(7) CD56dim cytotoxic NK 
cells have been hypothesized to have a role in the progression of the disease and, 
interestingly, also CD8+ T cells expressing perforin, representing another cytotoxic 
lymphocyte subset, have been proposed to play a role in disability progression both 
in Theiler’s murine encephalomyelitis virus model of MS  (8,9) and in human 
studies.(10,11) The reduction in CD56dim cytotoxic NK cells, along with CD4+ and 
CD8+ memory T cells, crucial in the MS pathophysiology,(12–14) in patients on DMF 
(6) is therefore relevant.  
Secondly, DMF may facilitate mitochondrial function, that pathological studies show 
to be altered in progressive MS,(15) with alterations of ATP synthesis, permeability 
transition pore opening, release of proapoptotic factors, electron transport chain and 
ionic homeostasis dysfunction.(15) 
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For all of these reasons, we would support on-going testing of DMF in SPMS.  
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